Yara Abdou

Sign up for free to read our exclusive June web feature! 🔐
This feature explores the evolution of the HER2-positive #BreastCancer landscape, including data from the neoCARHP and CompassHER2 pCR trials. @ptarantinomd.bsky.social @jamouabbi.bsky.social @yabdoumd.bsky.social

Today I graduate with my Master’s in Clinical Research. Grateful for the journey, the mentors who lifted me, the family who stood beside me, and the purpose that keeps me moving forward: advancing science that serves everyone
#Onward
@unclineberger.bsky.social
@uncpublichealth.bsky.social

Genomic assays have transformed BC care but they’re not the full story.
Our review @JAMAOnc shows that racial gaps in outcomes persist, even after accounting for molecular features —urging a more holistic approach to precision medicine.
@unclineberger.bsky.social

jamanetwork.com/journals/jam...

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial - Nature Medicine In a first-in-human phase 1 trial, HER2-specific CAR macrophages were feasible to manufacture and well tolerated, with no dose-limiting toxicities in patients with HER2-overexpressing solid tumors.

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
@naturemedicine.bsky.social @yabdoumd.bsky.social
www.nature.com/articles/s41...

Analysis of RxPONDER trial data by @yabdoumd.bsky.social, et al, in JNCI highlights persistent racial disparities in #breastcancer outcomes.
doi.org/10.1093/jnci...
#bcsm #HealthDisparities @unclineberger.bsky.social @ibcresearch1.bsky.social @raalbany.bsky.social @jrgralow.bsky.social

Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4

#SABCS2024
#bcsm
@sabcs.bsky.social

So great seeing you @raalbany.bsky.social !!